CHELSEA ELLIS: Open Payments
NPI 1194147538 · SOUTHGATE, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,059 in 54 payments from 15 companies in 2025. Trend: 2023 $907 · 2024 $754 · 2025 $1,059
Food & beverage: $1,059
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 11 | $252 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $246 |
| Otsuka America Pharmaceutical, Inc. | 4 | $82 |
| Novo Nordisk Inc | 5 | $77 |
| GlaxoSmithKline, LLC. | 4 | $76 |
| Xeris Pharmaceuticals, Inc. | 3 | $63 |
| PFIZER INC. | 3 | $48 |
| AstraZeneca Pharmaceuticals LP | 2 | $41 |
| Verona Pharma, Inc. | 2 | $38 |
| Merck Sharp & Dohme LLC | 2 | $34 |
Products named: CAPLYTA, VRAYLAR, REXULTI, Wegovy, TRELEGY ELLIPTA, GVOKE HYPOPEN, NURTEC ODT, Ohtuvayre.
Industry payments across MI — which companies pay providers there.
